Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: Role of cyclooxygenase-2

Clinical and Experimental Metastasis

Volumn 21, Issue 2, 2004, Pages 167-176

  Holzer, Ryan G ^a,c   Ryan, Randall E ^b   Tommack, Matt ^a   Schlekeway, Eric ^a   Jorcyk, Cheryl L ^a  

^a BOISE STATE UNIVERSITY   (United States)

^b Boise VA Medical Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Cell adhesion; Cyclooxygenase 2; Invasion; Metastasis; Oncostatin M

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ONCOSTATIN M; PROSTAGLANDIN E2; COLLAGEN; CYTOKINE RECEPTOR; GLYCOPROTEIN GP 130; ISOENZYME; LAMININ; MATRIGEL; MESSENGER RNA; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; OSM PROTEIN, MOUSE; PEPTIDE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEOGLYCAN; SULFONAMIDE; TUMOR PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CELL ADHESION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; IN VITRO STUDY; METASTASIS; MONOLAYER CULTURE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG CONTRAINDICATION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL ADHESION; CELL LINE, TUMOR; COLLAGEN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DEXAMETHASONE; DINOPROSTONE; DRUG COMBINATIONS; FEMALE; ISOENZYMES; LAMININ; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NITROBENZENES; ONCOSTATIN M; PEPTIDES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEOGLYCANS; RECEPTORS, CYTOKINE; RECEPTORS, ONCOSTATIN M; RNA, MESSENGER; SULFONAMIDES;

EID: 2942729997     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CLIN.0000024760.02667.db     Document Type: Article

References (45)

1. Gomez-Lechon MJ. Oncostatin M: Signal transduction and biological activity. Life Sci 1999: 65: 2019-30.
2. Grant SL, Begley CG. The oncostatin M signaling pathway: Reversing the neoplastic phenotype? Mol Med Today 1999; 5: 406-12.
3. Crichton MB, Nichols JE, Zhao Y et al. Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells. Mol Cell Endocrinol 1996; 118: 215-20.
4. Lopez MJ, Porter KA. Inflammatory breast cancer. Surg Clin North Am 1996; 76: 411-29.
5. Mantovani A, Bottazi B, Colotta F et al. The origin and function of tumor associated macrophages. Oncol Today 1992; 13: 265-70.
6. Aeed PA, Nakajima M, Welch DR. The role of polymorphonuclear leukocytes (PMN) on the growth and metastatic potential of 13762NF mammary adenocarcinoma cells. Int J Cancer 1988; 42: 748-59.
7. Welch DR, Schissel DJ, Howry RP, Aeed PA. Tumor-elicited polymorphonuclear cells, in contrast to 'normal' circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc Natl Acad Sci USA 1989; 86: 5859-63.
8. Bernard C, Merval R, Lebret M et al. Oncostatin M induces interleukin-6 and cyclooxygenase-2 expression in human vascular smooth muscle cells: Synergy with interleukin-1β. Circ Res 1999; 85: 1124-31.
9. Lahiri T, Laporte JD, Moore PE et al. Interleukin-6 family cytokines: Signaling and effects in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1225-L32.
10. Ohata Y, Harada T, Fujii A et al. Menstrual cycle-specific inhibition of endometrial stromal cell proliferation by oncostatin M. Mol Human Reprod 2001; 7: 665-70.
11. 2 and cyclooxygenase-2 in astrocytes: Synergy with interleukin-1β, tumor necrosis factor-α, and bacterial lipopolysaccharide. Glia 2003; 42: 433-46.
12. Khuder SA, Mutgi AB. Breast cancer and NSAID use: A meta-analysis. Br J Cancer 2001; 84: 1188-92.
13. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 2101-03.
14. Sharpe CR, Collet JP, McNutt M et al. Nested case control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000; 83: 112-20.
15. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteriodal drugs and breast cancer. Oncol Rep 1999; 6: 71-3.
16. Lala PK, Al-Mutter N, Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 1997; 73: 371-80.
17. Soslow RA, Dannenberg AJ, Rush D et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89: 2637-45.
18. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455-60.
19. Parrett ML, Harris RE, Joarder FS et al. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997; 10: 503-7.
20. Ristimaki A, Sivula A, Lundin J et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632-5.
21. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30: 3-21.
22. Connolly JM, Rose DP. Effects of fatty acids on invasion through reconstituted basement membrane ('Matrigel') by a human breast cancer cell line. Cancer Lett 1993; 75: 137-42.
23. Kakiuchi Y, Tsuji S, Tsujii M et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002; 62: 1567-72.
24. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-10.
25. Attiga FA, Fernandez PM, Weeraratna MJ et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000; 60: 4629-37.
26. Nithipatikom K, Isbell MA, Lindholm PF et al. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metast 2002; 19: 593-601.
27. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001; 93: 497-506.
28. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994; 91: 11236-40.
29. Holzer RG, MacDougall C, Cortright G et al. Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model. Breast Cancer Res Treat 2003; 77: 65-76.
30. Thomas B, Bird TA, Friend DJ. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem 1994; 269: 6215-22.
31. Mosley B, DeImus C, Friend D et al. Dual oncostatin M receptors. J Biol Chem 1996; 271: 32635-43.
32. Morriser S, Patry C, Lora M, de Brum-Fernandes J. Regulation of cyclooxygenase-2 expression in bovine chondrocytes in culture by interleukin 1alpha, tumor necrosis factor-alpha, glucocorticoids, and 17beta-estradiol. J Rheumatol 1998; 25: 1146-53.
33. Otto JC, DeWitt DL, Smith WL. N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientations in the endoplasmic reticulum. J Biol Chem 1993; 268: 18234-42.
34. Grant SL, Douglas AM, Goss GA, Begley CG. Oncostatin M and leukemia inhibitory factor regulate the growth of normal human breast epithelial cells. Growth Factors 2001; 19: 153-62.
35. Zarling JM, Shoyab M, Marquardt H et al. Oncostatin M: A growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci 1986; 83: 9739-43.
36. Horn D, Fitzpatrick WC, Gompper PT et al. Regulation of cell growth by recombinant oncostatin M. Growth Factors 1990; 2: 157-65.
37. Liu J, Spence MJ, Wallace PM et al. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene. Cell Growth Diff 1997; 8: 667-76.
38. Douglas AM, Goss GA, Sutherland RL et al. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 1997; 14: 661-9.
39. Zhang F, Cong L, Halfter H, Liu J. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 2003; 22: 894-905.
40. Douglas AM, Grant SL, Goss GA et al. Oncostatin M induces the differentiation of breast cancer cells. Int J Cancer 1998; 75: 64-73.
41. Tamm I, Kikuchi T, Cardindale I, Krueger JG. Cell-adhesion-disrupting action of interleukin 6 in human ductal breast carcinoma cells. Proc Natl Acad Sci USA 1994; 91: 3329-33.
42. Tamm I, Cardindale I, Kmeger J et al. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J Exp Med 1989; 170: 1649-69.
43. Zettl KS, Sjaastad MD, Riskin PM et al. Glucocorticoid-induced formation of tight junctions in mouse mammary epithelial cell in vitro. Proc Natl Acad Sci USA 1992; 89: 9069-73.
44. Percival MD, Bastien L, Griffin PR et al. Investigation of human cyclooxygenase-2 glycosylation heterogeneity and protein expression in insect and mammalian cell expression systems. Prot Exp Pur 1997; 9: 388-98.
45. Badache A, Hynes NE. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 2001; 61: 383-91.